Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Frank Nocken: FDA Approves Caplacizumab Therapy for Pediatric Acquired TTP
Frank Nocken/LinkedIn
Apr 6, 2026, 13:51

Frank Nocken: FDA Approves Caplacizumab Therapy for Pediatric Acquired TTP

Frank Nocken, Independent Consultant for Scientific Innovation Management, shared a post on LinkedIn:

“‘The FDA has approved Cablivi (caplacizumab) for injection to treat pediatric patients aged 12 years and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.’

‘Caplacizumab therapy is nanobody-based and built on small antibody fragments derived from heavy-chain-only antibodies, that targets von Willebrand factor, a protein that plays a central role in platelet adhesion and clot formation in aTTP.

It works by binding to the A1 domain of von Willebrand factor, blocking its interaction with platelets and helping to reduce the microvascular clots that define the disease.'”

Stay updated with Hemostasis Today.

 

 

aTTP Caplacizumab FDA Frank Nocken Headlines Health Hematology Hemostasis Hemostasis News Hemostasis Today Medicine Von Willebrand Factor
NewsFeed